MedRx Co., Ltd (TYO:4586)

Japan flag Japan · Delayed Price · Currency is JPY
79.00
-1.00 (-1.25%)
Apr 28, 2026, 3:30 PM JST
19.70%
Market Cap 4.69B
Revenue (ttm) 128.00M
Net Income (ttm) -937.00M
Shares Out 59.37M
EPS (ttm) -17.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 573,100
Average Volume 1,068,325
Open 80.00
Previous Close 80.00
Day's Range 78.00 - 81.00
52-Week Range 58.00 - 225.00
Beta 0.67
RSI 35.49
Earnings Date May 8, 2026

About MedRx

MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops transdermal medicines based on the ionic liquid transdermal system (ILTS) and the nano-sized colloid transdermal system (NCTS); and microneedle arrays/patch vaccines for the delivery of vaccines and APIs through the skin. Its products also include MRX-5LBT, which has NDA approval in the United States for neuropathic pain; MRX-4TZT, which is in a Phase II trial for spastic paral... [Read more]

Sector Healthcare
Founded 2002
Employees 21
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4586
Full Company Profile

Financial Performance

In 2025, MedRx's revenue was 128.00 million, a decrease of -50.19% compared to the previous year's 257.00 million. Losses were -937.00 million, 16.3% more than in 2024.

Financial Statements

News

There is no news available yet.